Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on January 22, 2013. The filing discloses the appointment of Dr. Dale Schenk as President and Chief Executive Officer of Prothena Biosciences Inc., an indirect wholly-owned subsidiary of the registrant. The employment agreement is effective as of December 21, 2012.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $450,000 annually.
- Annual Target Bonus: 60% of annual base salary (commencing in 2013).
- Stock Option Grant: 450,000 ordinary shares of Parent, exercisable at the average closing price between January 17, 2013, and January 29, 2013.
- Option Vesting: 25% on January 29, 2014, with the remainder vesting monthly thereafter (1/48th per month).
Material Changes
The primary material change is the leadership transition with the appointment of Dr. Schenk. The filing details specific severance arrangements that differ based on the timing of termination relative to a Change in Control:
- Termination Outside Change in Control: 150% of base salary, 100% of target bonus, and acceleration of equity vesting for an 18-month period.
- Termination Within Change in Control: 250% of base salary, 250% of target bonus, and 100% acceleration of unvested equity awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential cash outflow and equity dilution associated with the executive's severance packages, particularly in the event of a Change in Control.
Investor Verification Checklist
- Verify the exact exercise price of the 450,000 stock options once the January 29, 2013, closing price is finalized.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the impact of the 2012 prorated bonus from Dr. Schenk's prior employer (Elan Corporation PLC) on current period expenses.
- Assess the potential dilution impact of the 450,000 share option grant relative to the company's current outstanding share count.